ER
ESPR

Enlightenment Research’s Esperion Therapeutics ESPR Stock Holding History

Enlightenment Research’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-300
Closed -$14K – 281
2018
Q4 		$14K Buy
+300
New +$14.5K 0.02% 523

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Enlightenment Research's ESPR Position: Q1 2019 in Review

Enlightenment Research sold out of Esperion Therapeutics (ESPR) in Q1 2019, closing a stake of 300 shares — an estimated $14K sold.

Enlightenment Research first reported a position in ESPR in Q4 2018 and held it in 1 quarter. The position peaked at $14K in Q4 2018. 163 funds tracked by Wall St. Rank hold ESPR as of Q1 2019.

  • Enlightenment Research reported no remaining Esperion Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Enlightenment Research sold 300 Esperion Therapeutics shares in Q1 2019, an estimated $14K.
  • Enlightenment Research first reported a position in Esperion Therapeutics in Q4 2018 and held it in 1 quarter.
  • Enlightenment Research's Esperion Therapeutics position peaked at $14K in Q4 2018.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2019.

Based on Enlightenment Research's 13F filing for Q1 2019, filed 3 May 2019.